Background: Blood biomarkers are easily accessible and might reflect chronic obstructive pulmonary disease (COPD) activity.
| IN TRO DUCT IO N
Chronic obstructive pulmonary disease (COPD) affects 65 million people globally, including 15 million Americans. Over the past two decades, the disease has progressed from the fourth to the third leading cause of death in the USA and worldwide. [1] [2] [3] COPD classically consists of emphysema characterized by alveolar wall destruction with a loss of elastic recoil and of chronic bronchitis due to airway inflammation and remodeling. 4, 5 Beyond emphysema and chronic bronchitis, COPD is a complex and heterogeneous condition with several phenotypes resulting from different mechanisms and pathophysiology. 6 It involves not only airflow limitation but ican also lead to systemic manifestations (eg, cardiovascular, musculoskeletal, hematologic and metabolic). 7 At first, the forced expiratory volume in the first second of expiration (FEV1) was the sole marker of COPD severity. [6] [7] [8] However, given FEV1 limitations, other biomarkers have recently been of great interest as a way to better phenotype COPD, predict its prognosis and evaluate the efficacy of treatment. 7, 8 Some markers of inflammation such as fibrinogen have been found to be predictors of COPD exacerbation or death, 8 whereas other ones involved in inflammation
[such as C-reactive protein (CRP) neutrophils and eosinophils] and nutrition (albumin and vitamin D) are still under investigation. [9] [10] [11] [12] [13] Blood biomarkers are easily measured and can be systemic markers of COPD activity or they can reflective of substances released from lung into the bloodstream. 14 Yet, little is still known on their performance to predict COPD prognosis. Therefore, we aimed to study these biomarkers as potential predictors of long-term mortality COPD in a nationally representative sample of participants with COPD.
| MAT ERI AL S A ND M ETH ODS

| Data source and study design
We used data from the National Health and Nutrition Examination Survey (NHANES) conducted from 2007 to 2010 and the corresponding Mortality-Linked File. The NHANES is a continuous cross-sectional survey of the US noninstitutionalized civilian population conducted by the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). It uses a complex multistage sampling design to derive a representative sample of the US population. Of the 12 153 adult participants to the NHANES between 2007 and 2010, 590 were identified as having COPD. Among them, 447 had data on mortality after follow-up through December 31, 2011. Data on the biomarkers of interest were available on 431 participants who were included in our study. NHANES participants were matched to the National Death Index (NDI) records and death certificates were used for additional confirmation. The cause of death was determined based on the underlying cause listed on the death certificates, coded using the International Classification of Diseases, Tenth Revision (ICD-10).
| COPD definition and analysis of biomarkers
Eligible NHANES participants aged 20-79 years underwent baseline spirometry, including forced vital capacity (FVC) and FEV1. Examinees with baseline FEV1/FVC <70% or less than lower limit of normal (LLN) for their age, sex, weight, height and race/ethnicity were considered for postbronchodilator (albuterol) spirometry. COPD was defined as post-bronchodilator FEV1/forced vital capacity (FVC) ratio <70%. Because participants receiving daytime oxygen therapy were excluded from spirometry testing for safety reasons, we classified those who reported COPD diagnosis (chronic bronchitis or emphysema) and were currently taking supplemental oxygen during the day as having COPD. CRP was quantified in NHANES by latex-enhanced nephelometry. Eosinophils and neutrophils were part of the complete blood count parameters assessed with the Beckman Coulter method and white blood cell differential used VCS technology. The percentages of eosinophils and neutrophils were derived from the white blood cells scatterplot. Serum albumin was measured using the DcX800 method as a bichromatic digital endpoint method. 25-hydroxyvitamin D3 (25OHD3) was measured using an ultra-high-performance liquid chromatography-tandem mass spectrometric method. Detailed description of all these methods are reported on the NHANES website (https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear52009).
Blood biomarkers were dichotomized using cut-offs reported in the literature. We categorized CRP as normal if 1 mg/dL and high if >1 mg/dL. The CRP cutoff of 1 mg/ dL is also used to discriminate between low and intermediate to high cardiovascular risk. 15 We classified neutrophil count as normal (70%) or high (>70%). 16 Eosinophil count was divided into levels 2% or <2%, the cutoff used in previous studies. 17 Serum albumin was considered as low if <30 g/dL or normal if 30 g/dL, 18 and serum vitamin D was defined as low if <50 nmol/L and normal if 50 nmol/L. 19 
| Demographics and comorbidities
The NHANES collected data on age, gender, race/ethnicity, poverty income ratio (PIR), cigarette smoking, body mass index (BMI) and medical conditions. Diabetes was defined by self-reported physician diagnosis, fasting plasma glucose 126 mg/dL, 2-hour oral glucose tolerance test 200 mg/dL or glycohemoglobin 6.5%. 20 Hypertension was defined by self-reported physician diagnosis or mean systolic blood pressure (of up to four measurements on two separate occasions) >140 mm Hg. Other comorbid conditions included reported diagnosis of asthma and history of stroke or myocardial infarction (MI).
| Statistical analysis
Descriptive analysis was performed, and because blood eosinophils and CRP were significantly skewed, they were log-transformed to improve the normality of their distribution. We explored the correlation between the biomarkers by means of the Pearson method to calculate correlation coefficients (r). Since the assumption of proportionality was violated, the traditional Cox proportional hazards regression modeling could not be used, instead the parametric Weibull survival analysis was used to estimate the hazard ratio (HR) and corresponding 95% confidence interval (CI) for mortality associated with each biomarker. It allows examining the effect of biomarkers on mortality in term of HR and whether it is increasing, decreasing or constant over time. The models were adjusted for age, gender, race/ethnicity, smoking, PIR, BMI and comorbidities (asthma, diabetes, hypertension, history of stroke or MI). We reported the risks of mortality for each biomarker used both as a continuous and dichotomized variable. Although the dichotomization reduces statistical power, it was done for clinical relevance, using clinically relevant cutoffs reported in the literature. We also assessed whether biomarkers might interact to affect mortality by including a product term in the models. The discriminative power or ability of the model to predict mortality was evaluated using the C-statistic, and the added predictive value of the biomarkers was assessed. NHANES sample weights were used in all analyses to obtain unbiased national estimates. The analyses were performed in SAS (Version 9.4) and STATA (Version 14). P values <.05 were considered statistically significant in all analyses.
| RES UL TS
| Descriptive analysis
Our sample consisted of 431 participants who were followed for a median time of 36 months with a maximum duration of 60 months. During follow-up, 38 participants (8.6%) died. There were weak (-0.3 < r -0.1 or 0.1 < r 0.3) to moderate (-0.5 < r -0.3 or 0.3 < r 0.5) correlations between some of the biomarkers. Log-CRP and neutrophils were weakly related, while vitamin D weakly correlated with log-eosinophils, neutrophils and albumin. Moderate associations occurred between log-CRP and albumin and between log-eosinophils and neutrophils (data not shown). The characteristics of participants are shown in Table  1 . In summary, participants with high CRP were 8.6% of the study sample. Compared to those with normal CRP, they were older and had a higher prevalence of hypertension and a history of MI/stroke. They also had a significantly lower FEV1 and a higher mortality. The prevalence of participants with high neutrophil count was 12.4%. Compared to those with normal neutrophil count, they were more likely to be smokers and to have a higher mortality. About 30.7% of participants had eosinophil count <2%. Compared to participants with eosinophil count 2%, they were mostly women, non-Hispanic Blacks, smokers. They had lower FEV1 and higher mortality. Low albumin was present in 1.5% of participants who, compared to those with normal albumin, were mainly women, or participants with diabetes, hypertension, history of stroke or MI, low FEV1 and higher mortality. The prevalence of low vitamin D was 17.9%. Compared to participants with normal vitamin D, they were mostly women, non-Hispanic Black, participants with obesity, asthma, diabetes, history of MI/stroke and lower FEV1 (Table 1) .
| Biomarkers and risk of mortality
In regression analysis adjusted for covariates and using biomarkers as continuous variables, Increasing CRP (HR 4.45, 95% CI: 1.91-10.37) and neutrophil count (HR 1.07, 95% CI: 1.03-1.11) was associated with higher mortality. However, decreasing eosinophil count correlated with a higher risk of death (HR: 7.03, 95% CI: 2.05-24.01). In addition to neutrophil count, neutrophil-to-lymphocyte ratio (NLR) was associated with a higher mortality (HR: 1.48, 95% CI: 1.28-1.72) ( Table 2) .
When the biomarkers were dichotomized, higher mortality in COPD was predicted by high CRP (HR: 3.95, 95% CI: 1.27-12.31; Figure 1A ), high neutrophil count (HR: 2.53, 95% CI: 1.07-6.00; Figure 1B ) and eosinophil count <2% (HR: 2.54, 95% CI: 1.06-6.08; Figure 1C ). Serum albumin ( Figure 1D ) and vitamin D ( Figure 1E ) had no effect COPD prognostic ( Table 2 ). The number of participants and deaths in each category of the biomarkers associated with mortality (high CRP, high neutrophils count and eosinophil count <2%) is reported in Figure 2 .
CRP and eosinophils significantly interacted to affect mortality (interaction P-value <.001). In stratified analysis by CRP levels, decreasing eosinophil was associated with higher mortality in participants with normal CRP (HR 10.05, 95% CI: 2.28-44.30) but not in those with high CRP. Because of the small number of COPD-specific mortality (only eight COPD deaths), we could not examine the association of the biomarkers with this outcome. Still, participants who subsequently died of COPD had significantly higher baseline levels of CRP (P 5 .0087) and neutrophil count (P 5 .010). Table 3 reports the predictive value (C-statistic) of different models. The initial model, which included age, gender, race/ ethnicity, PIR, smoking, BMI and comorbidities (diabetes, hypertension, history of MI/stroke) had a C-statistic of 0.79 (95% CI: 0.71-0.86). Its predictive value did not significantly improve with the addition of any of the individual biomarkers. However, the addition of CRP with eosinophils and/or neutrophil significantly improve the predictive value of the initial model (Table 3 ). Figure 3 displays the improvement in receiver operating characteristic (ROC) area (similar to the C-statistic) of the model with the highest predictive value. It included CRP, eosinophils and NLR added to the initial model. 
| Prediction of COPD prognosis
| DI S CU S S I ON
The current study uses a sample from the US population to examine the prediction of mortality in COPD by blood biomarkers such as CRP, eosinophils, neutrophils, albumin and vitamin D. The results suggest that high CRP and neutrophil count as well as low eosinophil levels were associated with death in COPD. Low eosinophil count was only associated with increased mortality risk in patients with low CRP. The addition of CRP and eosinophils and/or neutrophilia to the initial model significantly improved the prediction of mortality.
Consistent with our results, several studies found CRP to be a strong predictor of mortality in COPD. [21] [22] [23] This was confirmed by a recent meta-analysis of 15 studies and 11 180 participants, which showed a solid association of CRP with late (after 24 months) mortality in COPD. | However, the study failed to find a significant association with early mortality (<24 months of follow-up). 24 Other investigations have also reported that elevated CRP in COPD may be associated with decreased lung function, 25 lower quality of life, 26 more frequent exacerbation and hospital admission. [27] [28] [29] Moreover, COPD patients with high CRP hospitalized for exacerbations seem more likely to experience treatment failure than those with lower CRP concentration. 30 CRP is a known risk factor for cardiovascular mortality in both COPD and non-COPD subjects. 31 Although our analysis did not include COPD death as an outcome because of the small number of outcome events, baseline CRP was higher in participants who later died of COPD than in those who survived or died of other causes during followup. At the contrary of CRP, the literature on blood neutrophil count and COPD prognosis is scarce and has yielded conflicting results. In the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) cohort, 1843 COPD participants were followed for 3 years and blood neutrophil count was found to be associated with higher mortality. 23 Other authors have advocated for the use of the blood NLR as a promising biomarker of inflammation. 6 Log-CRP 6 log-eosinophils 6 neutrophils 0.84 (0.78, 0.91) 60.060 .023
24
6 Log-CRP 6 log-eosinophils 6 NLR 0.85 (0.78, 0.91) 60.063 .019
Abbreviations: CRP, C-reactive protein; NLR, neutrophils lymphocytes ratio. Initial model included age, gender, race/ethnicity, BMI, smoking, PIR, asthma, diabetes, hypertension, history of stroke or MI. Bold and underline indicates significant C-statistics and effect on the initial C-statistic as well as the corresponding P-values. Consistent with our results, NLR has been shown to be associated with both mortality and COPD severity. 13, 21, 32 Although NLR had strong association with mortality in our analysis, it did not have a predictive value significantly different from that of blood neutrophil count. We found that low eosinophil count was a strong predictor of poor prognosis in COPD. Consistent with our findings, a study conducted in a respiratory intensive care unit reported that COPD participants admitted for exacerbations with acute respiratory failure had longer length of hospital stay and poorer survival if their initial blood eosinophil count was 2%. 33 Bafadhel et al also observed that, among patients admitted for COPD exacerbation, those with blood eosinophils 2% or 200 cells/lL had a shorter length of hospital stay. 34 Similar results were found in a study of 137 patients with COPD hospitalized in Italy. 17 Studying the effect of asthma-like features on the clinical course of COPD in Japan, Suzuki et al also found that blood eosinophils <300 cells/lL was associated with a significantly faster decline in post-bronchodilator FEV1. 35 With regard to pulmonary infections, it has been suggested that in COPD, a low eosinophil count correlated with more frequent bacterial infections and a higher bacterial load of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae. Furthermore, there are several reports that high blood eosinophil count in COPD is associated with better response to corticosteroid therapy. 9, 36, 37 Abnormally low eosinophil count (eosinopenia) could also be an indicator of bacterial infection and might therefore be associated with poor survival in COPD patients. 38 The authors speculated that osteopenia in bacterial infections might be the consequence of circulating eosinophil chemotaxis and sequestration in tissues. 38 It is worth noting that in our study, only one participant had eosinopenia as defined in previous studies by eosinophil count <0.40/mm 3, 39 Conflicting with these findings, other research suggests that blood eosinophils are associated with increased risk of COPD exacerbation and hospital admissions. 39, 40 The role of eosinophils in COPD and the reason why low eosinophil counts may be associated with poor prognosis in COPD is unclear. Eosinophils originate from the bone marrow and migrate to the digestive and thymus organs. Under pathologic conditions, they travel to the lungs and stimulate the secretion of cytokines and cytotoxic granules, leading to eosinophilic inflammation. 41 At the contrary of circulating eosinophils involved in inflammatory processes, tissueresident eosinophils seem to be beneficial to the respiratory system by regulating to the homeostasis of immune processes and protecting the lungs against inflammation. 42 Interestingly, we found that the association between lower eosinophil count and increased mortality in COPD was observed only in the absence of inflammation. Our study was one of a very few to evaluate the predictive value of blood biomarkers on COPD prognosis. Using the C-statistic Celli et al assessed the addition of inflammatory biomarkers in their initial model which included age, the BODE index (BMI, FEV1, dyspnea and 6-minute walk distance) and previous COPD hospitalizations. 23 29 The mechanism by which inflammation could predict COPD prognosis might be due to the role of lung and airway inflammation in COPD progression and severity. 24 This also supported by our finding of lower lung function in participants with higher CRP, and neutrophils and the fact that participants who died of specifically of COPD had higher baseline CRP and neutrophil count. It is also possible that inflammation could contribute to atherosclerosis and cardiovascular diseases, leading to higher death in COPD patients. However, unlike previous reports, our initial prediction model included important comorbidities such asthma, diabetes, hypertension, history of stroke or MI, all associated with mortality. In the absence of inflammation, we found lower eosinophil count to be predictive of mortality in COPD and more importantly, the combination of both CRP and eosinophil count had the higher improvement in the prediction of mortality in COPD. Our study had limitations. Serum biomarkers were only measured once at baseline and their temporal stability is still unclear. We did not have data on COPD exacerbation to analyze it as an outcome. Other predictors of mortality in COPD such as exercise tolerance (6MWD), dyspnea (mMRC), fatfree mass and exacerbations were not measured. Because of the small number of COPD-specific death, it could not be examined as an outcome in the survival analysis. Nonetheless, our study had major strengths. It used a prospective design and its sample was selected from the general US population, which contributes to the generalizability of the findings. An additional strength is that we examined the predictive value of inflammatory biomarkers, taking into account important comorbidities, some of which were missing in previous studies. These were rigorously defined using both self-reports of doctor diagnosis and complementary tests to capture unreported cases.
FIGU RE 3
In conclusion, high levels of inflammatory markers such as CRP and neutrophils as well as low eosinophil count (especially in the absence of inflammation) predict poor mortality in COPD. The combination of CRP and eosinophil and/or neutrophil count significantly improves the mortality prediction. Future studies could evaluate whether interventions aimed at modifying the levels of these biomarkers can have an effect on COPD prognosis.
